Arvinas Inc
Change company Symbol lookup
Select an option...
ARVN Arvinas Inc
PAYX Paychex Inc
PYR Pyrogenesis Canada Inc
PM Philip Morris International Inc
GWAV Greenwave Technology Solutions Inc
SLNO Soleno Therapeutics Inc
VRPX Virpax Pharmaceuticals Inc
FDCFF Forum Energy Metals Corp
AFMD Affimed NV
FOUR Shift4 Payments Inc

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Arvinas, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The Company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The Company develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.

Closing Price
Day's Change
-0.46 (-2.21%)
B/A Size
Day's High
Day's Low

10-day average volume:

SF Intra-city Received Stock Exchange's Approval for Conversion of Unlisted Shares

3:54 am ET July 26, 2023 (PR Newswire) Print

Proactively Promoting Liquidity of Shares and Circulating Market Value

Hangzhou SF Intra-city Industrial Co., Ltd. ("SF Intra-city" or the "Group") (Stock Code: 9699.HK), China's largest third-party on-demand delivery service provider, is pleased to announce that on 25 July, the Group received approval from the Stock Exchange for the listing and dealing of a total of 451,403,783 H shares, which represent approximately 48.36% of the Group's total issued Shares.

The conversion and listing of H shares will involve 18 participating holders of unlisted shares, and they will participate in the conversion of H shares. Once the conversion and listing of the shares are completed on the Stock Exchange, SF Intra-city's total number of H shares is expected to increase from 310,289,026 to 761,692,809 significantly. This surge represents a remarkable increase in the approximate percentage of issued H shares from 33.24% to 81.60% of the Group's total shares. The listing of the converted H shares on the Stock Exchange is currently expected to commence by the end of this month.

SF Intra-city emphasised that the shares conversion and listing are important measures to further enhance the Group's brand value in the capital market. This move is conducive to bolstering the Group's reputation and competitiveness domestically and internationally while also enhancing operational efficiency, optimizing conporate structures and enhancing profitability. Additionally, the measure will significantly promote the liquidity, trading volume and turnover rate of SF Intra-city's shares, consequently contributing to the increase in circulating market value. The Group also expects a turnaround from losses to profits in the first half of 2023. SF Intra-city will continue focusing on high-quality growth, improved profitability, and steady development, aiming to deliver greater value returns to its shareholders and investors.

View original content:

SOURCE SF Intra-city

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.